Ezetimibe + Simvastatin
Axocar contains the active substances ezetimibe and simvastatin. Axocar is a medicine used to
reduce the level of total cholesterol, "bad" cholesterol (LDL cholesterol) and fatty substances called
triglycerides in the blood. Additionally, Axocar increases the level of "good" cholesterol (HDL cholesterol).
Axocar works through 2 mechanisms that reduce cholesterol levels. The active substance ezetimibe reduces
the absorption of cholesterol in the digestive tract. The active substance simvastatin, which belongs to a
class of medicines called "statins", inhibits the production of cholesterol in the body.
Cholesterol is one of several fatty substances present in the blood. Total cholesterol consists mainly of
LDL cholesterol and HDL cholesterol.
LDL cholesterol is often called "bad" cholesterol because it can accumulate on the walls of arteries, forming
plaques. Eventually, these plaques can cause narrowing of the arteries, which can limit or block blood flow to
important organs, such as the heart and brain. Blocking blood flow can lead to a heart attack or stroke.
HDL cholesterol is often called "good" cholesterol because it helps prevent the accumulation of bad cholesterol
in the arteries and protects against heart disease.
Triglycerides are another type of fat present in the blood, which can contribute to an increased risk of developing
heart disease.
Axocar is used in patients for whom diet alone is not enough to control cholesterol levels. During treatment
with this medicine, a cholesterol-reducing diet should be followed.
Axocar is used as a complementary treatment to a cholesterol-reducing diet in the following cases:
Axocar does not affect weight loss.
In case of doubt about taking any of the above-mentioned medicines, consult a doctor.
Before starting treatment, inform your doctor:
The doctor should perform a blood test before starting Axocar treatment and during treatment, if the patient has any liver disorders. The test will assess liver function.
The doctor may also perform blood tests to assess liver function after starting Axocar treatment.
During therapy, the doctor will closely monitor the patient's health if they have diabetes or are at risk of developing diabetes. The risk of developing diabetes is higher in people who have high blood sugar and fat levels, are overweight, and have high blood pressure.
Avoid taking Axocar and fibrates (certain cholesterol-lowering medicines) at the same time, as no studies have been conducted on the simultaneous use of Axocar and fibrates.
Axocar is not recommended for children under 10 years of age.
Tell your doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take, including those containing any of the following active substances. Taking Axocar with any of the following medicines may increase the risk of muscle problems (some of which are listed in the "Do not take Axocar" section):
tkliwości or bólu mięśni (rabdomioliza). Dodatkowe informacje dotyczące rabdomiolizy
znajdują się w punkcie 4.
Tell your doctor or pharmacist about all medicines the patient has recently taken, including those available without a prescription. In particular, tell your doctor if the patient is taking any of the following:
Also, inform any doctor who prescribes a new medicine that the patient is taking Axocar.
Grapefruit juice contains one or more components that increase the metabolism of some medicines, including Axocar. Grapefruit juice should be avoided, as it may increase the risk of muscle problems.
Do not take Axocar if the patient is pregnant, planning to become pregnant, or suspects they may be pregnant. If the patient becomes pregnant while taking Axocar, they should stop taking the medicine and consult a doctor immediately. Do not take Axocar while breastfeeding, as it is not known whether the medicine passes into breast milk.
Before taking any medicine, consult a doctor or pharmacist.
It is not expected that Axocar will affect driving or using machines. However, consider that some people may experience dizziness after taking Axocar.
Axocar contains lactose and sodium.
Axocar tablets contain a sugar called lactose. If the patient has previously been diagnosed with intolerance to some sugars, they should consult a doctor before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which means it is "sodium-free".
The doctor will determine the dose of Axocar suitable for the patient, depending on the current treatment and individual risk.
This medicine should always be taken as directed by a doctor or pharmacist. In case of doubt, consult a doctor or pharmacist.
Adults: the recommended dose is 1 tablet, taken orally, once a day.
Use in adolescents (10-17 years): the recommended dose is 1 tablet, taken orally, once a day (do not exceed the maximum dose of 10 mg + 40 mg per day).
The dose of Axocar, 10 mg + 80 mg, is recommended only for adult patients with very high cholesterol levels and a high risk of heart disease, who have not achieved target cholesterol levels with lower doses.
If optimal dosing cannot be achieved with Axocar, the doctor may prescribe other tablets containing ezetimibe with simvastatin.
Tablets do not have a dividing line and should not be divided.
Axocar should be taken in the evening. It can be taken with or without food.
If the doctor has prescribed Axocar and another cholesterol-lowering medicine containing the active substance cholestyramine or another bile acid sequestrant, Axocar should be taken at least 2 hours before or 4 hours after taking the bile acid sequestrant.
Consult a doctor or pharmacist.
Do not take a double dose to make up for a missed dose; take the usual dose of Axocar the next day at the usual time
Consult a doctor or pharmacist, as cholesterol levels may rise again.
In case of further doubts about taking this medicine, consult a doctor or pharmacist.
Like all medicines, Axocar can cause side effects, although not everybody gets them (see section 2).
The following side effects have been reported commonly(may affect up to 1 in 10 people):
The following side effects have been reported uncommonly(may affect up to 1 in 100 people):
The following side effects have been reported rarely(may affect up to 1 in 1000 people):
The following side effects have been reported very rarely(may affect up to 1 in 10,000 people):
Additional possible side effects reported in patients taking some statins:
death has occurred.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181 C
02 222 Warsaw
Phone: + 48 22 49 21 301
Fax: + 48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can be reported to the marketing authorization holder or its representative in Poland.
Reporting side effects will help gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the carton and packaging after "EXP".
The expiry date refers to the last day of the month.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substances of Axocar are ezetimibe and simvastatin.
Each tablet contains 10 mg of ezetimibe and 10 mg of simvastatin.
Each tablet contains 10 mg of ezetimibe and 20 mg of simvastatin.
Each tablet contains 10 mg of ezetimibe and 40 mg of simvastatin.
Each tablet contains 10 mg of ezetimibe and 80 mg of simvastatin.
Other ingredients are:
Core:lactose monohydrate, hypromellose, sodium croscarmellose, microcrystalline cellulose, ascorbic acid, citric acid, butylhydroxyanisole (BHA), propyl gallate, magnesium stearate.
Color mixture:lactose monohydrate, yellow iron oxide (E 172), red iron oxide (E 172), and black iron oxide (E 172).
Axocar, 10 mg+10 mg, are light brown, speckled, round tablets with a diameter of 6 mm, convex on both sides with the marking "511" on one side.
Axocar, 10 mg+20 mg, are light brown, speckled, round tablets with a diameter of 8 mm, convex on both sides with the marking "512" on one side.
Axocar, 10 mg+40 mg, are light brown, speckled, round tablets with a diameter of 10 mm, convex on both sides with the marking "513" on one side.
Axocar, 10 mg+80 mg, are light brown, speckled, capsule-shaped tablets with dimensions of 17.5x7.55 mm, convex on both sides with the marking "515" on one side.
Packaging sizes
Blisters.
Axocar, 10 mg+10 mg: 10, 30, 50, 100, and 300 tablets.
Axocar, 10 mg+20 mg, 10 mg+40 mg, 10 mg+80 mg: 30, 50, 100, and 300 tablets.
Not all packaging sizes may be available.
Zentiva, k.s., U kabelovny 130, Dolní Měcholupy, 102 37 Prague 10, Czech Republic
Balkanpharma-Dupnitsa AD, 3 Samokovsko Shosse Street, 2600 Dupnitsa, Bulgaria
This medicinal product is authorized in the Member States of the European Economic Area under the following names:
Denmark: Ezimvalla
Germany: Ezetimib Simvastatin
Italy: Ezetimibe e Simvastatina Zentiva
Portugal: Sinvastatina + Ezetimiba Zentiva
Slovakia: Cornusan
Poland : Axocar
Date of last revision of the leaflet:September 2021
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.